Two Innovative Biotech Firms from Simbay Park Named to '2024 ChinaBang 100 Future Unicorns'

Dec 24, 2024 17:29 CST Updated 17:29

Epigenic

Gene Editing Technology Developer

Amidst the profound adjustments in the global economic landscape and the complex geopolitical environment, technological innovation and the digital economy have become crucial solutions. Despite the challenges of trade frictions and industrial chain restructuring faced by various countries, this has instead elevated the strategic importance of unicorn companies and potential unicorn enterprises, making them a significant measure of a nation's innovative competitiveness.

Recently,Xingbei·FTO No.1 Park Companies Epigenic and Westlake Bio Honored on "2024 CYZONE 100 Future Unicorn" ListAccording to the selection data from the past few years, the selected companies typically achieved significant valuation growth within just a few years of their establishment and have set important benchmarks in the industry. Epigenic and Westlake Bio have successfully made it onto this list with their innovative breakthroughs and potential in their respective fields, becoming one of the most notable emerging companies in the industry.

Epigenic

Since its establishment, Epigenic has focused on utilizing epigenetic technology to regulate gene transcription, driving therapeutic solutions from the lab to clinical applications, and has achieved breakthrough progress in multiple major disease areas. The company’s developed EPI-003 (a treatment for hepatitis B) has received IND approval from New Zealand and Australia, with the first clinical trial expected to commence in the first quarter of 2025. Additionally, Epigenic has made significant advancements in the application of UCAR-T cell therapy and gene regulation technology.

Dr. BaoHong Zhang, Co-founder and CEO of Epigenic, Personally Attends the 2024 Bang Entrepreneur 100 Future Unicorn Conference and Participates in the Key Dialogue Session on the Afternoon of December 19, Sharing the Company’s Experience and Insights on Technological Innovation, Financing Journey, and Future Development Strategy. This is a Valuable Opportunity for In-depth Exchange with Industry Elites and Investment Institutions, and Epigenic Will Further Expand Its Cooperation and Development Space in the Biotechnology Field.

Westlake Bio

Westlake Biomedical Technology Co., Ltd. (Westlake Therapeutics) is the first biotechnology innovation company transformed from Westlake University. The company was established in2020Year6Officially launched in October, headquartered in the Westlake University Science Park located in Hangzhou's Yunqi Town, and2022Year1Established a research and production integrated center in the Shanghai Free Trade Zone No.1 Life Science Park in [Month].

Westlake Bio has innovatively developed the world's leading engineered red blood cell technology platform, REDx, which leverages the natural enrichment of red blood cells in immune organs for engineering modifications to enable them to activate immune cells. The company has established multiple First-in-Class cell therapy R&D pipelines targeting major diseases such as cancer, immunity, and metabolism. The first innovative achievement, WTX-212, has entered the clinical trial stage, demonstrating excellent efficacy and safety as a monotherapy in end-stage solid tumor patients resistant to immunotherapy, and has achieved the first-ever complete cure with a red blood cell drug in solid tumor patients. Currently, Westlake Bio has preliminarily built a highly automated "All-in-One" red blood cell drug production line, equipped with a GMP pilot production workshop, capable of meeting the clinical needs of a large patient population.

About SimbayPark

Shanghai FT1 Life Science Park (abbreviation"Simbay Park, Star North Free Trade Zone No.1 Project" is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the Star North Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique "FTAs + bonded" outward-oriented economic regional advantages. By gathering the entire industry chain service resources of CRO+CDMO+CSO+EHS in biomedicine, government innovation and entrepreneurship support policies, and numerous well-known investment institutions, the park provides enterprises with truly in-depth technical incubation in the medical industry, becoming a steward for the transformation of corporate technological achievements, and is committed to building an international biomedical industry innovation and entrepreneurship base.